Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence

European Journal of Cancer

Volumn 40, Issue 2, 2004, Pages 284-290

  Wildiers, H ^a   Ahmed, B ^a   Guetens, G ^a   De Boeck, G ^a   De Bruijn, E A ^a   Landuyt, W ^a   Van Oosterom, A T ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Combretastatin A 4 phosphate; CPT 11; Timing; Tumour uptake

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; COMBRETASTATIN A 4; COMBRETASTATIN A-4; COMBRETASTATIN A4; DRUG DERIVATIVE; IRINOTECAN; STILBENE DERIVATIVE;

ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIVISION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG INTERACTION; DRUG POTENTIATION; EVALUATION; HUMAN; METABOLISM; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; RAT; RHABDOMYOSARCOMA; TIME; TUMOR MODEL;

EID: 0346023954     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.09.006     Document Type: Article

References (19)

1. Griggs J., Metcalfe J.C., Hesketh R. Targeting tumour vasculature. the development of combretastatin A4 Lancet Oncol. 2:2001;82-87.
2. Dowlati A., Robertson K., Cooney M.et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 62:2002;3408-3416.
3. Dark G.G., Hill S.A., Prise V.E., Tozer G.M., Pettit G.R., Chaplin D.J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57:1997;1829-1834.
4. Siemann D.W., Mercer E., Lepler S., Rojiani A.M. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int. J. Cancer. 99:2002;1-6.
5. Furman W.L., Stewart C.F., Poquette C.A.et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J. Clin. Oncol. 17:1999;1815-1824.
6. Vassal G., Pondarre C., Boland I.et al. Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. Biochimie. 80:1998;271-280.
7. Kaneda N., Nagata H., Furuta T., Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 50:1990;1715-1720.
8. Machida Y., Onishi H., Kurita A., Hata H., Morikawa A., Machida Y. Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats. J. Control Release. 66:2000;159-175.
9. Chaplin D.J., Hill S.A., Bell K.M., Tozer G.M. Modification of tumor blood flow. current status and future directions Semin. Radiat. Oncol. 8:1998;151-163.
10. Pedley R.B., Sharma S.K., Boxer G.M.et al. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res. 59:1999;3998-4003.
11. Siim B.G., Lee A.E., Shalal-Zwain S., Pruijn F.B., McKeage M.J., Wilson W.R. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother. Pharmacol. 51:2003;43-52.
12. Grosios K., Loadman P.M., Swaine D.J., .Pettit G.R., Bibby M.C. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res. 20:2000;229-233.
13. Landuyt W., Verdoes O., Darius D.O.et al. Vascular targeting of solid tumours. a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas Eur. J. Cancer. 36:2000;1833-1843.
14. Wildiers H., Guetens G., De Boeck G.et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br. J. Cancer. 88:2003;1979-1986.
15. Pruijn F.B., van Daalen M., Holford N.H., Wilson W.R. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol. 39:1997;541-546.
16. Murata R., Siemann D.W., Overgaard J., Horsman M.R. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother. Oncol. 60:2001;155-161.
17. Atsumi R., Okazaki O., Hakusui H. Metabolism of irinotecan to SN-38 in a tissue-isolated tumor model. Biol. Pharm. Bull. 18:1995;1024-1026.
18. Bibby M.C., Loadman P.M., al Ghabban A.F., Double J.A. Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice. Br. J. Cancer. 65:1992;347-350.
19. Bibby M.C., Sleigh N.R., Loadman P.M., Double J.A. Potentiation of EO9 anti-tumour activity by hydralazine. Eur. J. Cancer. 29A:1993;1033-1035.